GE Ventures and Mayo Clinic have teamed-up to launch Vitruvian Networks, an independent platform company committed to accelerating access to cell and gene therapies through cloud-ready software systems and manufacturing services.
Vitruvian Networks will partner with therapy producers and provide them with software and manufacturing platform to bring the Internet of Things (IoT) to cell and gene therapies. At scale, the platform will be a “network orchestrator” for therapeutic companies with powerful business intelligence and data analytics capabilities. It will help its clients with time and resource-intense processes to provide personalized therapies to patients. This in turn could expedite the transition of promising and potentially curative therapies from early clinical trials to a portfolio of products that advances medical care.
Initially, Vitruvian Networks will focus on the production of autologous cell therapies that target blood cancers. The company also will develop the supporting standards, infrastructure and ecosystem that will protect patients and expedite discovery, delivery and regulation in the field.
“Autologous therapies in the area of regenerative and personalized medicine have shown great promise in treating life-threatening diseases,” Andre Terzic, M.D., Ph.D., director of the Mayo Clinic Center for Regenerative Medicine, said in a statement. “We are excited that Vitruvian Networks will further drive standardization of the industry, increase scalability and bring forward the realization of critical therapeutic potential to address the unmet needs of patients around the world.”
For the partnership, Mayo Clinic will provide its data related to biomarkers, cell therapy processes and clinical outcomes to guide further development of personalized therapies. On the other hand, GE Healthcare will make its cell therapy business available Vitruvian, as well as access the GE Store, which is deemed a global exchange of knowledge, technology and tools from across the company.